Journal of Medical Genetics and Genomics
Subscribe to JMGG
Full Name*
Email Address*

Article Number - D4B07C242845


Vol.6(1), pp. 11-18 , January 2014
DOI: 10.5897/JMGG2013.0069
ISSN: 2141-2278



Full Length Research Paper

A study of correlation between CYP2C9 gene polymorphism and Warfarin maintenance dose in anticoagulant therapy among Han people in Yunnan of China



ZhiYu Chen
  • ZhiYu Chen
  • Affiliated Yan An Hospital of Kunming Medical University, Kunming, Yunnan Province, P.R. China.
  • Google Scholar
Jintao Li
  • Jintao Li
  • Neuroscience Institution of Kunming Medical University, Kunming, Yunnan Province, P.R. China.
  • Google Scholar
Xuemei Dong
  • Xuemei Dong
  • Institute of Criminal Science and Technology of Lin Cang Police, Bureau, Lin Cang, Yunnan Province, P.R. China.
  • Google Scholar
JianXing Liu4
  • JianXing Liu4
  • Forensic Medicine College of Kunming Medical University, Kunming, Yunnan Province, P.R. China.
  • Google Scholar
Hui Gao
  • Hui Gao
  • Affiliated Yan An Hospital of Kunming Medical University, Kunming, Yunnan Province, P.R. China.
  • Google Scholar
Liping Zhao
  • Liping Zhao
  • Forensic Medicine College of Kunming Medical University, Kunming, Yunnan Province, P.R. China.
  • Google Scholar
BingYing Xu
  • BingYing Xu
  • Forensic Medicine College of Kunming Medical University, Kunming, Yunnan Province, P.R. China.
  • Google Scholar







 Accepted: 25 March 2013  Published: 31 January 2014

Copyright © 2014 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0


In this study, we investigated the correlation between CYP2C9 gene polymorphism and maintenance dose of Warfarin in 300 patients who were the Han population derived from the Affiliated Yan An Hospital of Kunming Medical University in Yunnan Province of China, subjected to the operation of cardiac valve replacement and Warfarin oral administration post operation from 2008 to 2009 by detecting the genotypes and Allele Frequency at the three candidate loci (CYP2C9*2,CYP2C9*3 and CYP2C9*c_65) of CYP2C9 gene from the blood samples. Polymerase chain reaction -restriction fragment length polymorphism (PCR-RFLP) assay and DNA sequencing were used to ascertain the genotypes and their corresponding distribution rate. The maintenance dose of Warfarin administered in anticoagulant therapy among the CYP2C9*3 genetypes found in our experiment showed: A/A wild type > A/C heterozygote>C/C homozygote, suggesting that patients with C mutation need the lowest maintenance dose of Warfarin among the three genotypes found in this study. Our results will shed a new light on the personalized medicine of Warfarin and provide basic and genetic experimental data and foundation for future studies with regard to multiple genes’ effect on Warfarin dorsage in anticogulantant therapy.

Key words: Warfarin, maitenance dosage, CYP2C9, gene polymorphism, single nucleotide polymorphism (SNP), restriction fragment length polymorphism (RFLP), correlation.

Abbreviation:

INR, International normalized ratio; PT, prothrombin time; SNP, single nucleotide polymorphism.


Aithal GP, Day CP, Kesteven PJL, Daly AK (1999).Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-719.
Crossref
 
Alessandra P, Emma RT, Francis PS, David P, William HG, Sam M, Hibberd V, Holden J, Courtenay O, Wellington EM (2011). Pathogen Quantitation in Complex Matrices: A Multi-Operator Comparison of DNA Extraction Methods with a Novel Assessment of PCR Inhibition. PLoS One 6:e17916.
Crossref
 

Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, Park YS, Lee SY(2005). Allele and genotype frequencies of CYP2C9 in a Korean population. Br . J. Clin. Pharmacol. 60:4l8-422.

View

 
Chern HD, Ueng TH, Fu YP, Cheng CW (2006). CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chin. Clin. Chim. Acta. 367:108-13.
Crossref
 
Garcia-Martin E, Martinez C, Ladero JM, Gamito FJ, Agúndez JA (2001). High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur. J. Clin. Pharmacol. 57(1):47-49.
Crossref
 
Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Lainscak M, Mrhar A, Breskvar K, Dolzan V (2006).The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur. J. Clin. Pharmacol. 62:291-296.
Crossref
 
Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srin-ouanp rachanh SL, Farin FM, Rettie AE (2002). Association between CYP2C9 genetic variants and anticoagulati on2related outcomes during warfarin therapy. JAMA 287:1690 - 1698.
Crossref
 
Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE (2002). Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287: 1690-1698.
Crossref
 
Hong X, Zhang S, Mao G, Jiang S, Zhang Y, Yu Y, Tang G, Xing H, Xu X(2005). CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur. J. Clin. Pharlnacol. 61627-634.
 
Joanna J, Agnieszka M, Ryszard P (2012). Comparison of three methods of DNA extraction from human bones with different degrees of degradation. Int. J. Legal Med. 126:173-178.
Crossref
 
Lazarou J, Pomeranz BH, Corey PN (1998). Incidence of adverse drug reactions in hospitalized patients: ameta-analysis of prospective studies.JAMA, 279:1200-1205.
Crossref
 
Levine MN, Raskob G, Landefeld S, Kearon C (2001). Hemorrhagic complications of anticoagulant treatment.Chest, 119:108S-121S.
Crossref
 
Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, Ezra D (2001). Inter-individual variability in sensitivity to warfarin nature or nurture. Clin. Phannacol. Ther. 70:159-164.
Crossref
 
Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G (2000).Genetic modulation of oral anticoagulation with warfarin.Thromb. Haemost. 84:775-778.

View

 
Mizutani T (2003). PM frequencies of major CYPs in Asians and Caucasians. Drug Metab, 35:99-106.
Crossref
 
Nakai K, Habano W, Nakai K, Fukushima N, Suwabe A, Moriya S, Osano K, Gurwitz D (2005). Ethnic differences in CYP2C9 * 2(Arg144Cys) and CYP2C9* 3(Ile359Leu)genotypes in Japanese and Israeli populations. Life Sci. 78: 107-111.
Crossref
 
Quick AJ (1935b). The prothrombin time in hemophilia and in obstructive jaundice. J. Biol. Chem. 109:73-74.
 
Quick AJ, Stanley-Brown M, Bancroft FW (1935a). A study of the coagulation defect in hemophilia and in jaundice. Am. J. Med. Sci.190:501-511.
Crossref
 
Sanderson S, Emery J, Higgins J (2005). CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients:a Hu-Genet-systematic review and meta-analysis. Genet. Med. 7:97-104.
Crossref
 
Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F (2005). The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329-33.
Crossref
 
Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M (2001).Genetic polymorphism of cytochrome P450 2C9 in a Caucasian an d a black African population. Br. J. Clin. Pharmacol. 52(4):447-450.
Crossref
 
Taube J, Halsall D, Baglin T (2000). Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96:1816-1819.

PubMed

 
Yu BN, Luo CH, Wang D, Wang A, Li Z, Zhang W, Mo W, Zhou HH (2004). CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin. Chim. Acta 348:57-61.
Crossref

 


APA Chen, Z. Y., Li, J., Dong, X., Liu, J. X., Gao, H., Zhao L., & Xu, B. Y. (2014). A study of correlation between CYP2C9 gene polymorphism and Warfarin maintenance dose in anticoagulant therapy among Han people in Yunnan of China. Journal of Medical Genetics and Genomics, 6(1), 11-18.
Chicago ZhiYu Chen, Jintao Li, Xuemei Dong, JianXing Liu, Hui Gao, Liping Zhao and BingYing Xu. "A study of correlation between CYP2C9 gene polymorphism and Warfarin maintenance dose in anticoagulant therapy among Han people in Yunnan of China." Journal of Medical Genetics and Genomics 6, no. 1 (2014): 11-18.
MLA ZhiYu Chen, et al. "A study of correlation between CYP2C9 gene polymorphism and Warfarin maintenance dose in anticoagulant therapy among Han people in Yunnan of China." Journal of Medical Genetics and Genomics 6.1 (2014): 11-18.
   
DOI 10.5897/JMGG2013.0069
URL http://academicjournals.org/journal/JMGG/article-abstract/D4B07C242845

Subscription Form